Search

Learn how tiny sensors made of nanotubes could serve as implantable devices that offer a noninvasive way to monitor cancer and its treatments.

… Tuesday, March 14, 2017 Summary It is difficult to monitor diseases like cancer without repeated biopsies and imaging scans. A solution could be offered by the field of nanotechnology , in the form of tiny sensors made up of carbon nanotubes. The sensors could be implanted under the skin, and a small

Dr. Bob Li will present registrational phase II data from the first-ever trial of a drug that blocks cancer gene KRAS.

… Friday, January 29, 2021 International scientists, researchers, physicians and patient advocates in the field of lung cancer and thoracic malignancies will tune in January 28-31, 2021, for the 2020 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer

… Monday, September 16, 2024 Selwyn M. Vickers, MD, FACS , the President and CEO of Memorial Sloan Cancer Center, is a renowned pancreatic cancer surgeon, health equity researcher, and hospital leader. But the title he is proudest of is ‘Dad.’  Dr. Vickers and his wife, Janice, have raised four grown children

A recently approved treatment approach dramatically improves the outlook for people with an aggressive form of lymphoma.

… Friday, February 8, 2019 Summary People newly diagnosed with peripheral T cell lymphoma have traditionally been treated with chemotherapy. A recent study showed that adding a drug called brentuximab vedotin to chemotherapy could stop the disease from progressing and improve survival. Peripheral T cell

Three faculty members from Memorial Sloan Kettering Cancer Center (MSK) and Sloan Kettering Institute (SKI) have been elected to the 2021 class of American Association for the Advancement of Science (AAAS) Fellows.

… Thursday, January 27, 2022 Three faculty members from Memorial Sloan Kettering Cancer Center (MSK) and Sloan Kettering Institute (SKI) have been elected to the 2021 class of American Association for the Advancement of Science (AAAS) Fellows. The new class of AAAS Fellows includes 564 scientists, engineers

Researchers from Memorial Sloan Kettering Cancer Center (MSK) are pioneering a new groundbreaking clinical trial for children and young adults with relapsed or treatment-resistant acute lymphocytic leukemia (ALL) by using one of the most promising methods of cancer treatment today, chimeric antigen receptor (CAR) T cells.

… Thursday, April 9, 2015 Researchers from Memorial Sloan Kettering Cancer Center (MSK) are pioneering a new groundbreaking clinical trial for children and young adults with relapsed or treatment-resistant acute lymphocytic leukemia (ALL) by using one of the most promising methods of cancer treatment today

The combination immunotherapy of talimogene laherparepvec (T-VEC) and pembrolizumab met its primary endpoint of objective response rate at 24 weeks in our phase II clinical trial in patients with advanced sarcoma.

… Thursday, June 11, 2020 The combination immunotherapy of talimogene laherparepvec (T-VEC) and pembrolizumab met its primary endpoint of objective response rate at 24 weeks in our phase II clinical trial in patients with advanced sarcoma.  (1) The best objective response rate (ORR) was 30 percent (95%

Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments:

… Thursday, July 28, 2022 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments: Ya-Ting Wang and Inaki Etxberria Ya-Ting “Emma” Wang and Inaki Etxberria Receive Prestigious Early Career Researcher Awards Ya-Ting “Emma” Wang , postdoctoral fellow, was named the 2022

Learn how a novel drug is showing promise against lung and pancreatic cancer in early clinical trials by targeting the KRAS G12D mutation with a KRAS degrader.

… Wednesday, March 25, 2026 A new drug is showing promise in lung and pancreatic cancers — two of the most aggressive forms of cancer — by targeting one of the most common cancer-driving mutations. Setidegrasib, formerly known as ASP3082, tags and destroys the cancer-causing protein produced by the KRAS

Anthony DeMaio spent much of his younger life hiding from the spotlight. Today, he lives authentically in his personal and professional life. He also embraces the spotlight more figuratively — through a number of appearances on the small screen.

… Wednesday, June 22, 2022   Anthony DeMaio, senior physician relations liaison at MSK Anthony DeMaio, senior physician relations liaison at MSK Anthony DeMaio spent much of his younger life hiding from the spotlight. Today, he lives authentically in his personal and professional life. He also embraces